Cellectis SA (ALCLS) AI Stock Analysis

• Market Cap: $117.80M
• Dividend Yield: N/A
• Average Volume (3M): 116.57K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.65
• Revenue Growth: 833.95%
• EPS Growth: 38.17%
• Country: FR
• Employees: 216
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): -0.16
• Shares Outstanding: 72,093,636
• 10 Day Avg. Volume: 223,075
• 30 Day Avg. Volume: 116,572
• PEG Ratio: 0.05
• Price to Book (P/B): 1.78
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 5.91
• Enterprise Value/Market Cap: 0.96
• Enterprise Value/Revenue: 0.86
• Enterprise Value/Gross Profit: 2.40
• Enterprise Value/Ebitda: -0.44
• 1Y Price Target: $1.50
• Price Target Upside: -5.26% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 51 Neutral
• Price Target: €1.50 ▼(-5.06%Downside)

Cellectis SA's overall stock score is weighed down by its challenging financial performance, marked by persistent losses and a negative P/E ratio. However, the technical analysis shows strong bullish momentum, providing some optimism. The lack of earnings call details and corporate events leaves a gap in qualitative assessment.

Cellectis SA Business Overview & Revenue Model

Company Description

Cellectis SA is a leading biopharmaceutical company specializing in the development of gene-editing technologies and therapies. Headquartered in Paris, France, the company operates primarily in the biotechnology and healthcare sectors. Cellectis is renowned for its pioneering work in developing allogeneic CAR-T cell therapies, which are designed to treat various types of cancer by leveraging advanced gene-editing techniques.

How the Company Makes Money

Cellectis SA generates revenue through a combination of product sales, licensing agreements, and collaboration partnerships. The company develops and commercializes gene-edited cell and gene therapies, particularly focusing on its allogeneic CAR-T cell products. Revenue streams include milestone payments and royalties from licensing its proprietary gene-editing technologies to other biotechnology and pharmaceutical companies. Additionally, Cellectis partners with major industry players to co-develop and commercialize therapies, sharing both the risks and the financial rewards. These collaborations often involve upfront payments, research funding, and potential future royalties upon successful commercialization of products.

Cellectis SA Financial Statement Overview

Summary

Cellectis SA is struggling financially with negative net profit and EBITDA margins, despite some revenue growth. Cash flow improvements are noted, but persistent operating losses and a pressured equity position highlight significant financial challenges.

Income Statement

Cellectis SA's income statement reflects a challenging financial position with a negative net profit margin and declining EBIT. Despite an increase in revenue in the TTM period, the company continues to struggle with profitability, as evidenced by the negative net income and EBITDA margins. Revenue growth shows potential, but persistent operating losses need addressing.

Balance Sheet

The balance sheet of Cellectis SA displays a relatively stable equity position and an improving debt-to-equity ratio, indicating controlled leverage. However, the company faces a challenge with maintaining a positive equity ratio amidst high liabilities. The decrease in stockholders' equity over the past periods suggests potential financial strain, requiring close monitoring.

Cash Flow

Cellectis SA shows improvement in cash flow management with a positive operating cash flow in the TTM period. Free cash flow has increased, albeit from a negative base, indicating better cash accrual from operations. However, the free cash flow to net income ratio indicates that net income remains negative, highlighting ongoing profitability challenges.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	41.51M	755.00K	19.17M	73.95M	73.95M
Gross Profit	41.51M	18.00K	17.40M	37.67M	37.67M
EBITDA	-9.46M	-92.64M	-76.38M	-85.44M	-43.34M
Net Income	-36.76M	-101.06M	-98.69M	-86.28M	-72.57M
Balance Sheet
Total Assets	383.54M	334.27M	261.22M	382.08M	469.47M
Cash, Cash Equivalents and Short-Term Investments	260.31M	203.81M	97.70M	186.13M	268.24M
Total Debt	91.46M	85.06M	82.85M	102.24M	111.30M
Total Liabilities	252.51M	249.57M	135.28M	145.60M	160.63M
Stockholders Equity	131.03M	84.69M	117.97M	221.29M	275.57M
Cash Flow
Free Cash Flow	19.15M	-25.82M	-89.89M	-124.31M	-126.52M
Operating Cash Flow	22.99M	-24.75M	-87.44M	-104.56M	-80.26M
Investing Cash Flow	-102.81M	-15.51M	-2.76M	7.28M	-54.34M
Financing Cash Flow	89.11M	82.86M	1.15M	47.52M	27.32M

Cellectis SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.58
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALCLS, the sentiment is Positive. The current price of 1.58 is above the 20-day moving average (MA) of 1.37, above the 50-day MA of 1.35, and above the 200-day MA of 1.51, indicating a bullish trend. The MACD of 0.08 indicates Negative momentum. The RSI at 67.04 is Neutral, neither overbought nor oversold. The STOCH value of 68.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ALCLS.

Cellectis SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NANO	57 Neutral	€215.33M	―		―	―	―
Sector *	55 Neutral	€4.62B	17.03	-50.16%	3.66%	15.32%	-9.52%
ALCLS	51 Neutral	$117.80M	―	-58.55%	―	833.95%	38.17%
ALSEN	46 Neutral	€91.08M	―	-49.28%	―	―	55.02%
TNG	44 Neutral	€104.06M	―	-220.48%	―	-97.04%	-32.53%

Cellectis SA Corporate Events

Cellectis Reports 2024 Financial Results and Strategic Advances in CAR T-Cell Therapies

Cellectis has announced its financial results for the fourth quarter and fiscal year 2024, alongside a business update. The company is advancing its clinical trials, particularly UCART22 and UCART20x22, with significant regulatory designations from the FDA and European Commission, enhancing its position in the CAR T-cell therapy market. Its strategic partnership with AstraZeneca, including a $140 million investment, supports the development of next-generation genomic medicines, with a strong cash position projected to last until mid-2027.

Cellectis Advances Clinical Programs and Strengthens AstraZeneca Partnership

Cellectis has reported its financial results for the fourth quarter and full year 2024, highlighting significant progress in its clinical programs and strategic partnerships. The company is advancing its UCART22 and UCART20x22 programs, with key data readouts expected in 2025. Cellectis has also strengthened its collaboration with AstraZeneca, which includes an additional equity investment of $140 million, ensuring financial stability until mid-2027. The company’s focus remains on developing next-generation genomic medicines to address unmet patient needs.